Summary of Research: Health-Related Quality-of-Life Profile and Clinical Outcomes in First-Line Advanced Renal Cell Carcinoma: A Modeling Analysis Based on the CheckMate 9ER Study. (PubMed, Adv Ther) - Oct 9, 2026 - P3 | "CheckMate 9ER demonstrated a significant improvement in progression-free survival and overall survival with first-line cabozantinib plus nivolumab (CaboNivo) versus sunitinib (SUN) in patients with advanced renal cell carcinoma...LCA identified three distinct patient profiles at week 13; those in the limited symptoms class were more likely to have received CaboNivo and to have a longer treatment duration, and were generally less likely to experience disease progression than patients in other symptom classes. This analysis demonstrated a link between early changes in patient-reported outcomes and efficacy in the CheckMate 9ER study, highlighting the importance of balancing efficacy, tolerability, and HRQoL to optimize treatment outcomes and support shared decision-making.Trial Registration NCT03141177."
Clinical data • HEOR • Journal • Genito-urinary Cancer • Musculoskeletal Pain • Oncology • Pain • Renal Cell Carcinoma • Solid Tumor
|
|
Alessia Ogareva; Cristiane Bergerot; David Cella; Intan Purnajo; Jens Bedke; Lysbeth Floden; Michael DeRosa; Mickael Lothgren; Rachel H Giles; Robert J Motzer; Thomas Powles; Toni K Choueiri
|